LumiraDx Key Executives
This section highlights LumiraDx's key executives, including their titles and compensation details.
Find Contacts at LumiraDx
(Showing 0 of )
LumiraDx Earnings
This section highlights LumiraDx's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q2 | 2023 | 2023-08-24 | $-0.15 | $-0.16 |
| Read Transcript | Q1 | 2023 | 2023-05-16 | $-0.15 | $-0.14 |
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.
$0.02
Stock Price
$5.10M
Market Cap
413
Employees
London, None
Location
Financial Statements
Access annual & quarterly financial statements for LumiraDx, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Revenue | $254.48M | $421.43M | $139.15M | $23.14M |
| Cost of Revenue | $289.78M | $269.89M | $86.21M | $14.32M |
| Gross Profit | $-35.30M | $151.54M | $52.95M | $8.82M |
| Gross Profit Ratio | -13.87% | 36.00% | 38.05% | 38.11% |
| Research and Development Expenses | $141.63M | $130.22M | $107.54M | $86.55M |
| General and Administrative Expenses | $- | $130.52M | $46.13M | $37.29M |
| Selling and Marketing Expenses | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $144.51M | $130.52M | $46.13M | $37.29M |
| Other Expenses | $- | $36.20M | $- | $- |
| Operating Expenses | $287.32M | $296.94M | $153.67M | $123.84M |
| Cost and Expenses | $575.92M | $566.83M | $239.87M | $138.16M |
| Interest Income | $10.38M | $165.43M | $581.00K | $1.98M |
| Interest Expense | $134.56M | $117.94M | $31.60M | $17.19M |
| Depreciation and Amortization | $33.29M | $25.71M | $-17.72M | $-12.17M |
| EBITDA | $-273.54M | $45.74M | $-118.44M | $-127.19M |
| EBITDA Ratio | -107.49% | 10.85% | -85.11% | -549.62% |
| Operating Income | $-321.45M | $20.02M | $-100.72M | $-115.02M |
| Operating Income Ratio | -126.32% | 4.75% | -72.38% | -497.02% |
| Total Other Income Expenses Net | $-121.84M | $47.49M | $-150.22M | $-27.63M |
| Income Before Tax | $-443.29M | $-97.92M | $-250.94M | $-142.65M |
| Income Before Tax Ratio | -174.20% | -23.24% | -180.34% | -616.41% |
| Income Tax Expense | $4.32M | $2.84M | $-9.95M | $-9.54M |
| Net Income | $-449.19M | $-100.76M | $-241.00M | $-133.11M |
| Net Income Ratio | -176.52% | -23.91% | -173.19% | -575.18% |
| EPS | $-1.59 | $-0.62 | $-0.95 | $-0.53 |
| EPS Diluted | $-1.59 | $-0.62 | $-0.95 | $-0.53 |
| Weighted Average Shares Outstanding | 282.24M | 162.79M | 252.70M | 252.70M |
| Weighted Average Shares Outstanding Diluted | 282.24M | 163.26M | 252.70M | 252.70M |
| SEC Filing | Source | Source | Source | Source |
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.00M | $22.17M | $41.12M | $42.22M | $44.73M | $126.41M | $118.25M | $109.08M | $87.22M | $106.87M | $112.28M | $13.93M | $34.79M | $34.79M | $5.79M | $5.79M | $5.79M | $5.79M |
| Cost of Revenue | $30.91M | $23.93M | $139.92M | $33.59M | $39.89M | $76.39M | $63.73M | $70.24M | $72.36M | $63.55M | $65.87M | $12.88M | $21.55M | $21.55M | $3.58M | $3.58M | $3.58M | $3.58M |
| Gross Profit | $-9.90M | $-1.76M | $-98.80M | $8.63M | $4.84M | $50.03M | $54.52M | $38.84M | $14.86M | $43.32M | $46.41M | $1.05M | $13.24M | $13.24M | $2.21M | $2.21M | $2.21M | $2.21M |
| Gross Profit Ratio | -47.14% | -7.90% | -240.30% | 20.40% | 10.80% | 39.60% | 46.10% | 35.60% | 17.00% | 40.50% | 41.34% | 7.53% | 38.05% | 38.05% | 38.11% | 38.11% | 38.11% | 38.11% |
| Research and Development Expenses | $15.83M | $19.48M | $21.61M | $31.25M | $47.45M | $41.32M | $33.82M | $35.40M | $34.26M | $26.74M | $27.70M | $27.92M | $26.88M | $26.88M | $21.64M | $21.64M | $21.64M | $21.64M |
| General and Administrative Expenses | $- | $- | $- | $35.31M | $- | $40.16M | $37.41M | $- | $- | $38.05M | $- | $- | $11.53M | $11.53M | $9.32M | $9.32M | $9.32M | $9.32M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $22.70M | $25.98M | $31.20M | $35.31M | $37.84M | $40.16M | $37.41M | $58.92M | $26.95M | $38.05M | $15.81M | $12.23M | $11.53M | $11.53M | $9.32M | $9.32M | $9.32M | $9.32M |
| Other Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-76.83M | $-76.83M | $-61.92M | $-61.92M | $-61.92M | $-61.92M |
| Operating Expenses | $38.53M | $45.46M | $52.81M | $66.57M | $85.30M | $81.47M | $76.63M | $94.32M | $61.21M | $64.79M | $43.51M | $40.15M | $-38.42M | $-38.42M | $-30.96M | $-30.96M | $-30.96M | $-30.96M |
| Cost and Expenses | $69.43M | $69.39M | $192.73M | $100.15M | $125.18M | $157.86M | $140.36M | $164.56M | $133.57M | $128.35M | $109.38M | $53.02M | $59.97M | $59.97M | $34.54M | $34.54M | $34.54M | $34.54M |
| Interest Income | $18.11M | $18.68M | $69.32M | $4.83M | $4.45M | $5.42M | $22.00K | $178.83M | $71.02M | $6.58M | $20.23M | $264.00K | $- | $- | $- | $- | $- | $- |
| Interest Expense | $19.06M | $15.11M | $15.74M | $88.18M | $- | $27.93M | $14.84M | $37.59M | $38.20M | $165.98M | $- | $27.97M | $7.90M | $7.90M | $4.30M | $4.30M | $4.30M | $4.30M |
| Depreciation and Amortization | $8.14M | $26.38M | $78.23M | $12.76M | $-69.99M | $8.40M | $9.16M | $7.72M | $4.63M | $4.07M | $4.23M | $2.54M | $-29.65M | $-29.65M | $-2.53M | $-2.53M | $-2.53M | $-2.53M |
| EBITDA | $-43.48M | $-20.84M | $-73.37M | $-45.18M | $-150.45M | $-17.62M | $-12.93M | $131.08M | $29.31M | $-10.82M | $-112.27M | $-36.30M | $-54.83M | $-54.83M | $-31.29M | $-31.29M | $-31.29M | $-31.29M |
| EBITDA Ratio | -207.03% | -93.97% | -178.43% | -107.01% | -336.37% | -13.94% | -10.93% | 120.16% | 33.61% | -10.12% | -100.00% | -260.60% | -157.62% | -157.62% | -540.83% | -540.83% | -540.83% | -540.83% |
| Operating Income | $-48.43M | $-47.22M | $-151.61M | $-57.93M | $-80.46M | $-31.45M | $-22.11M | $-55.48M | $-46.35M | $-21.48M | $2.90M | $-39.10M | $-25.18M | $-25.18M | $-28.75M | $-28.75M | $-28.75M | $-28.75M |
| Operating Income Ratio | -230.58% | -212.94% | -368.69% | -137.23% | -179.89% | -24.88% | -18.69% | -50.86% | -53.14% | -20.09% | 2.58% | -280.71% | -72.38% | -72.38% | -497.02% | -497.02% | -497.02% | -497.02% |
| Total Other Income Expenses Net | $-953.00K | $3.39M | $53.59M | $-83.35M | $-67.67M | $-22.51M | $-14.81M | $110.43M | $32.82M | $-159.40M | $-75.40M | $-27.71M | $-37.56M | $-37.56M | $-6.91M | $-6.91M | $-6.91M | $-6.91M |
| Income Before Tax | $-49.38M | $-43.64M | $-98.02M | $-141.29M | $-148.13M | $-53.95M | $-36.92M | $85.77M | $-13.53M | $-180.88M | $-72.50M | $-66.80M | $-62.74M | $-62.74M | $-35.66M | $-35.66M | $-35.66M | $-35.66M |
| Income Before Tax Ratio | -235.11% | -196.83% | -238.38% | -334.66% | -331.19% | -42.68% | -31.22% | 78.63% | -15.51% | -169.25% | -64.58% | -479.63% | -180.34% | -180.34% | -616.41% | -616.41% | -616.41% | -616.41% |
| Income Tax Expense | $294.00K | $480.00K | $4.18M | $2.14M | $-732.00K | $2.22M | $293.00K | $994.00K | $1.64M | $-87.00K | $-803.00K | $-4.47M | $-2.49M | $-2.49M | $-2.39M | $-2.39M | $-2.39M | $-2.39M |
| Net Income | $-49.74M | $-44.12M | $-102.20M | $-143.43M | $-147.40M | $-56.25M | $-37.34M | $84.74M | $-15.45M | $-180.83M | $-71.89M | $-62.37M | $-60.24M | $-60.24M | $-33.20M | $-33.20M | $-33.20M | $-33.20M |
| Net Income Ratio | -236.80% | -198.99% | -248.53% | -339.74% | -329.55% | -44.50% | -31.58% | 77.68% | -17.71% | -169.21% | -64.03% | -447.77% | -173.18% | -173.18% | -573.88% | -573.88% | -573.88% | -573.88% |
| EPS | $-0.16 | $-0.14 | $-0.33 | $-0.47 | $-0.48 | $-0.22 | $-0.15 | $0.99 | $-0.06 | $-0.72 | $-0.28 | $-0.25 | $-0.24 | $-0.24 | $-0.13 | $-0.13 | $-0.13 | $-0.13 |
| EPS Diluted | $-0.16 | $-0.14 | $-0.32 | $-0.47 | $-0.48 | $-0.22 | $-0.15 | $0.72 | $-0.06 | $-0.72 | $-0.28 | $-0.25 | $-0.24 | $-0.24 | $-0.13 | $-0.13 | $-0.13 | $-0.13 |
| Weighted Average Shares Outstanding | 318.88M | 315.80M | 314.22M | 304.41M | 304.41M | 253.07M | 252.70M | 133.55M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M |
| Weighted Average Shares Outstanding Diluted | 318.88M | 318.68M | 318.84M | 304.41M | 304.41M | 253.07M | 252.70M | 183.23M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M | 252.70M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Cash and Cash Equivalents | $100.01M | $132.15M | $158.72M | $139.39M |
| Short Term Investments | $- | $- | $- | $- |
| Cash and Short Term Investments | $100.01M | $132.15M | $158.72M | $139.39M |
| Net Receivables | $65.18M | $124.82M | $119.00M | $5.64M |
| Inventory | $89.97M | $149.06M | $85.52M | $11.91M |
| Other Current Assets | $- | $- | $13.43M | $22.99M |
| Total Current Assets | $266.94M | $406.02M | $376.66M | $179.93M |
| Property Plant Equipment Net | $129.99M | $201.10M | $97.47M | $28.10M |
| Goodwill | $14.66M | $15.61M | $15.99M | $15.39M |
| Intangible Assets | $17.51M | $21.44M | $24.73M | $26.14M |
| Goodwill and Intangible Assets | $32.17M | $37.05M | $40.72M | $41.53M |
| Long Term Investments | $11.42M | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- |
| Other Non-Current Assets | $497.00K | $569.00K | $241.00K | $-69.64M |
| Total Non-Current Assets | $174.07M | $238.72M | $138.43M | $69.64M |
| Other Assets | $- | $- | $- | $259.00K |
| Total Assets | $441.01M | $644.74M | $515.10M | $249.82M |
| Account Payables | $69.91M | $134.82M | $57.90M | $16.17M |
| Short Term Debt | $9.22M | $5.77M | $149.35M | $- |
| Tax Payables | $- | $- | $- | $- |
| Deferred Revenue | $7.99M | $40.46M | $45.80M | $- |
| Other Current Liabilities | $4.68M | $-40.46M | $35.59M | $23.18M |
| Total Current Liabilities | $91.80M | $140.60M | $288.63M | $39.34M |
| Long Term Debt | $380.62M | $330.36M | $148.72M | $360.19M |
| Deferred Revenue Non-Current | $15.77M | $20.99M | $- | $- |
| Deferred Tax Liabilities Non-Current | $397.00K | $779.00K | $1.23M | $- |
| Other Non-Current Liabilities | $57.80M | $-10.59M | $451.72M | $-360.19M |
| Total Non-Current Liabilities | $454.59M | $341.54M | $601.68M | $360.19M |
| Other Liabilities | $- | $- | $- | $3.12M |
| Total Liabilities | $546.39M | $482.14M | $890.31M | $402.65M |
| Preferred Stock | $- | $- | $- | $- |
| Common Stock | $858.09M | $177.81M | $152.73M | $152.69M |
| Retained Earnings | $-1.09B | $-676.64M | $-607.66M | $-369.87M |
| Accumulated Other Comprehensive Income Loss | $120.47M | $661.61M | $79.92M | $- |
| Other Total Stockholders Equity | $6.73M | $- | $- | $64.54M |
| Total Stockholders Equity | $-105.11M | $162.78M | $-375.01M | $-152.63M |
| Total Equity | $-105.38M | $162.60M | $-375.22M | $-152.83M |
| Total Liabilities and Stockholders Equity | $441.01M | $644.74M | $515.10M | $- |
| Minority Interest | $-267.00K | $-180.00K | $-207.00K | $-194.00K |
| Total Liabilities and Total Equity | $441.01M | $644.74M | $515.10M | $- |
| Total Investments | $11.42M | $- | $- | $- |
| Total Debt | $401.25M | $336.13M | $298.08M | $- |
| Net Debt | $301.24M | $203.98M | $139.36M | $-139.39M |
Balance Sheet Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $25.34M | $68.05M | $100.01M | $135.26M | $106.45M | $166.05M | $132.15M | $215.28M | $33.04M | $33.04M | $158.72M | $39.68M | $39.68M | $39.68M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $25.34M | $68.05M | $100.01M | $135.26M | $106.45M | $166.05M | $132.15M | $215.28M | $33.04M | $33.04M | $158.72M | $39.68M | $39.68M | $39.68M |
| Net Receivables | $52.31M | $64.60M | $76.96M | $68.11M | $59.88M | $93.62M | $124.82M | $106.41M | $26.12M | $26.12M | $119.00M | $29.75M | $29.75M | $29.75M |
| Inventory | $85.19M | $89.82M | $89.97M | $158.61M | $169.56M | $164.73M | $149.06M | $178.16M | $37.26M | $37.26M | $85.52M | $21.38M | $21.38M | $21.38M |
| Other Current Assets | $- | $- | $- | $- | $19.77M | $- | $- | $2.44M | $5.09M | $5.09M | $13.43M | $3.36M | $3.36M | $3.36M |
| Total Current Assets | $176.09M | $222.47M | $266.94M | $361.99M | $355.66M | $424.40M | $406.02M | $502.30M | $101.50M | $101.50M | $376.66M | $94.17M | $94.17M | $94.17M |
| Property Plant Equipment Net | $120.86M | $125.13M | $129.99M | $175.71M | $185.08M | $198.51M | $201.10M | $170.34M | $50.29M | $50.29M | $97.47M | $24.37M | $24.37M | $24.37M |
| Goodwill | $14.96M | $- | $14.66M | $- | $14.61M | $- | $15.61M | $- | $3.90M | $3.90M | $15.99M | $4.00M | $4.00M | $4.00M |
| Intangible Assets | $17.37M | $32.21M | $17.51M | $30.56M | $18.48M | $- | $21.44M | $- | $5.36M | $5.36M | $24.73M | $6.18M | $6.18M | $6.18M |
| Goodwill and Intangible Assets | $32.33M | $32.21M | $32.17M | $30.56M | $33.09M | $35.72M | $37.05M | $38.21M | $9.26M | $9.26M | $40.72M | $10.18M | $10.18M | $10.18M |
| Long Term Investments | $11.53M | $11.99M | $11.42M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $798.00K | $505.00K | $497.00K | $452.00K | $510.00K | $592.00K | $569.00K | $545.00K | $142.25K | $142.25K | $241.00K | $60.25K | $60.25K | $60.25K |
| Total Non-Current Assets | $165.52M | $169.84M | $174.07M | $206.72M | $218.68M | $234.83M | $238.72M | $209.09M | $59.69M | $59.69M | $138.43M | $34.61M | $34.61M | $34.61M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $341.61M | $392.31M | $441.01M | $568.71M | $574.34M | $659.23M | $644.74M | $711.40M | $161.19M | $161.19M | $515.10M | $128.77M | $128.77M | $128.77M |
| Account Payables | $65.99M | $63.58M | $69.91M | $87.20M | $45.92M | $106.13M | $134.82M | $191.14M | $14.93M | $14.93M | $57.90M | $14.47M | $14.47M | $14.47M |
| Short Term Debt | $310.29M | $8.63M | $9.22M | $6.60M | $6.61M | $5.88M | $5.77M | $5.43M | $47.75K | $47.75K | $149.35M | $36.81M | $36.81M | $36.81M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $14.16M | $15.44M | $7.99M | $30.68M | $33.52M | $35.66M | $40.46M | $- | $10.11M | $10.11M | $45.80M | $11.45M | $11.45M | $11.45M |
| Other Current Liabilities | $- | $- | $- | $- | $42.70M | $- | $-40.46M | $- | $11.00M | $11.00M | $35.59M | $9.43M | $9.43M | $9.43M |
| Total Current Liabilities | $390.45M | $87.65M | $87.12M | $124.49M | $128.76M | $147.67M | $140.60M | $196.57M | $36.09M | $36.09M | $288.63M | $72.16M | $72.16M | $72.16M |
| Long Term Debt | $92.47M | $391.43M | $392.02M | $378.87M | $380.98M | $381.02M | $330.36M | $321.83M | $75.28M | $75.28M | $148.72M | $34.93M | $34.93M | $34.93M |
| Deferred Revenue Non-Current | $14.45M | $14.45M | $15.77M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $333.00K | $397.00K | $408.00K | $537.00K | $676.00K | $779.00K | $910.00K | $194.75K | $194.75K | $1.23M | $307.50K | $307.50K | $307.50K |
| Other Non-Current Liabilities | $58.20M | $52.06M | $57.80M | $47.12M | $48.57M | $5.00M | $10.41M | $6.69M | $8.98M | $8.98M | $451.72M | $115.18M | $115.18M | $115.18M |
| Total Non-Current Liabilities | $165.11M | $458.27M | $466.00M | $426.40M | $430.09M | $386.70M | $341.54M | $329.43M | $84.46M | $84.46M | $601.68M | $150.42M | $150.42M | $150.42M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $555.55M | $545.91M | $553.12M | $550.89M | $558.84M | $534.37M | $482.14M | $526.00M | $120.55M | $120.55M | $890.31M | $222.58M | $222.58M | $222.58M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $858.43M | $858.25M | $858.09M | $853.51M | $758.11M | $755.10M | $177.81M | $769.22M | $188.51M | $188.51M | $152.73M | $38.18M | $38.18M | $38.18M |
| Retained Earnings | $-1.17B | $-1.12B | $-1.09B | $-996.42M | $-862.51M | $-724.50M | $-676.64M | $-690.21M | $-169.06M | $-169.06M | $-607.66M | $-151.91M | $-151.91M | $-151.91M |
| Accumulated Other Comprehensive Income Loss | $99.75M | $113.31M | $120.47M | $160.99M | $120.21M | $94.64M | $661.61M | $105.85M | $-7.68M | $-7.68M | $79.92M | $-3.71M | $-3.71M | $-3.71M |
| Other Total Stockholders Equity | $780.00K | $- | $- | $- | $- | $- | $- | $- | $28.88M | $28.88M | $- | $23.64M | $23.64M | $23.64M |
| Total Stockholders Equity | $-213.83M | $-153.43M | $-111.83M | $18.08M | $15.81M | $125.23M | $162.78M | $184.86M | $40.65M | $40.65M | $-375.01M | $-93.80M | $-93.80M | $-93.80M |
| Total Equity | $-213.95M | $-153.61M | $-112.10M | $17.81M | $15.49M | $124.86M | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Stockholders Equity | $341.61M | $392.31M | $441.01M | $568.71M | $574.34M | $659.23M | $644.74M | $711.40M | $161.19M | $161.19M | $515.10M | $128.77M | $128.77M | $128.77M |
| Minority Interest | $-118.00K | $-179.00K | $-267.00K | $-265.00K | $-316.00K | $-377.00K | $-180.00K | $537.00K | $- | $- | $-207.00K | $- | $- | $- |
| Total Liabilities and Total Equity | $341.61M | $392.31M | $441.01M | $568.71M | $574.34M | $659.23M | $644.74M | $711.40M | $161.19M | $161.19M | $515.10M | $128.77M | $128.77M | $128.77M |
| Total Investments | $11.53M | $11.99M | $11.42M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Debt | $402.76M | $400.06M | $401.25M | $385.48M | $387.59M | $386.90M | $336.13M | $327.26M | $75.33M | $75.33M | $298.08M | $71.74M | $71.74M | $71.74M |
| Net Debt | $377.41M | $332.01M | $301.24M | $250.21M | $281.14M | $220.85M | $203.98M | $111.98M | $42.29M | $42.29M | $139.36M | $32.06M | $32.06M | $32.06M |
Annual Cash Flow
| Breakdown | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|
| Net Income | $-447.61M | $-100.76M | $-241.00M | $-133.11M |
| Depreciation and Amortization | $33.29M | $25.71M | $10.91M | $8.00M |
| Deferred Income Tax | $-7.55M | $-4.66M | $-11.27M | $-9.55M |
| Stock Based Compensation | $35.21M | $33.91M | $3.19M | $3.97M |
| Change in Working Capital | $9.86M | $-69.09M | $-61.52M | $11.34M |
| Accounts Receivables | $53.32M | $-2.32M | $-95.53M | $6.39M |
| Inventory | $-2.27M | $-66.87M | $-73.30M | $-8.39M |
| Accounts Payables | $-39.53M | $-9.73M | $101.00M | $13.34M |
| Other Working Capital | $-1.67M | $9.83M | $6.32M | $- |
| Other Non Cash Items | $214.69M | $-19.85M | $150.35M | $27.60M |
| Net Cash Provided by Operating Activities | $-162.11M | $-134.88M | $-149.33M | $-91.75M |
| Investments in Property Plant and Equipment | $-24.98M | $-106.35M | $-64.38M | $-10.73M |
| Acquisitions Net | $- | $- | $- | $-581.00K |
| Purchases of Investments | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-683.00K |
| Net Cash Used for Investing Activities | $-24.98M | $-106.35M | $-64.38M | $-11.31M |
| Debt Repayment | $- | $- | $- | $- |
| Common Stock Issued | $98.00M | $38.57M | $- | $- |
| Common Stock Repurchased | $- | $16.16M | $- | $-2.04M |
| Dividends Paid | $- | $- | $- | $- |
| Other Financing Activities | $165.29M | $219.02M | $236.59M | $70.70M |
| Net Cash Used Provided by Financing Activities | $165.29M | $219.17M | $236.59M | $70.70M |
| Effect of Forex Changes on Cash | $-10.33M | $-6.96M | $-1.09M | $476.00K |
| Net Change in Cash | $-32.13M | $-29.03M | $21.79M | $-31.89M |
| Cash at End of Period | $100.01M | $132.15M | $161.17M | $139.39M |
| Cash at Beginning of Period | $132.15M | $161.17M | $139.39M | $171.27M |
| Operating Cash Flow | $-162.11M | $-134.88M | $-149.33M | $-91.75M |
| Capital Expenditure | $-24.98M | $-106.35M | $-64.38M | $-10.73M |
| Free Cash Flow | $-187.09M | $-241.23M | $-213.71M | $-102.48M |
Cash Flow Charts
| Breakdown | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 | September 30, 2019 | June 30, 2019 | March 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-49.68M | $-44.12M | $-102.20M | $-143.43M | $-147.40M | $-56.17M | $-37.21M | $84.77M | $-15.17M | $-180.79M | $-71.70M | $-62.33M | $-60.25M | $-60.25M | $-33.28M | $-33.28M | $-33.28M | $-33.28M |
| Depreciation and Amortization | $8.14M | $7.70M | $8.91M | $7.93M | $8.04M | $8.40M | $9.16M | $7.72M | $4.63M | $4.07M | $4.23M | $2.54M | $2.73M | $2.73M | $2.00M | $2.00M | $2.00M | $2.00M |
| Deferred Income Tax | $-397.00K | $-2.84M | $-4.77M | $-742.00K | $-565.00K | $-1.47M | $-1.82M | $-1.47M | $-685.00K | $-688.00K | $-2.06M | $-4.67M | $-2.82M | $-2.82M | $-2.39M | $-2.39M | $-2.39M | $-2.39M |
| Stock Based Compensation | $1.95M | $8.02M | $8.22M | $9.58M | $9.44M | $7.98M | $4.40M | $4.10M | $4.28M | $21.00M | $926.00K | $696.00K | $797.75K | $797.75K | $992.50K | $992.50K | $992.50K | $992.50K |
| Change in Working Capital | $5.53M | $9.25M | $16.54M | $-6.47M | $-19.37M | $17.03M | $-47.31M | $-456.00K | $-9.27M | $-12.06M | $-31.59M | $-30.71M | $-15.38M | $-15.38M | $2.83M | $2.83M | $2.83M | $2.83M |
| Accounts Receivables | $567.00K | $14.87M | $4.46M | $5.69M | $11.33M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $5.49M | $409.00K | $32.29M | $-2.27M | $-13.68M | $-18.61M | $26.12M | $-4.19M | $-31.15M | $-57.66M | $-41.48M | $-20.53M | $-18.33M | $-18.33M | $-2.10M | $-2.10M | $-2.10M | $-2.10M |
| Accounts Payables | $-527.00K | $-6.03M | $-18.55M | $-9.90M | $-17.02M | $3.80M | $-53.42M | $29.82M | $16.75M | $-2.89M | $86.57M | $8.29M | $25.25M | $25.25M | $3.33M | $3.33M | $3.33M | $3.33M |
| Other Working Capital | $- | $- | $-1.67M | $- | $11.33M | $31.84M | $-20.02M | $-26.09M | $5.13M | $48.49M | $-76.68M | $-18.48M | $-22.30M | $-22.30M | $1.60M | $1.60M | $1.60M | $1.60M |
| Other Non Cash Items | $7.44M | $-3.01M | $43.62M | $83.02M | $67.10M | $22.54M | $20.16M | $-119.15M | $-32.42M | $159.19M | $75.53M | $27.71M | $37.59M | $37.59M | $6.90M | $6.90M | $6.90M | $6.90M |
| Net Cash Provided by Operating Activities | $-27.02M | $-25.02M | $-29.68M | $-50.12M | $-82.74M | $-1.70M | $-52.63M | $-24.48M | $-48.63M | $-9.27M | $-24.66M | $-66.77M | $-37.33M | $-37.33M | $-22.94M | $-22.94M | $-22.94M | $-22.94M |
| Investments in Property Plant and Equipment | $-821.00K | $-1.73M | $-2.38M | $-5.88M | $-6.46M | $-10.26M | $-24.93M | $-19.68M | $-26.31M | $-35.43M | $-28.68M | $-9.14M | $-16.10M | $-16.10M | $-2.68M | $-2.68M | $-2.68M | $-2.68M |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $-36.28M | $38.24M | $-1.97M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $- | $- | $36.28M | $- | $- | $- | $- | $- | $16.10M | $16.10M | $2.68M | $2.68M | $2.68M | $2.68M |
| Net Cash Used for Investing Activities | $-821.00K | $-1.73M | $-2.38M | $-5.88M | $-6.46M | $-10.26M | $-24.93M | $18.57M | $-28.28M | $-35.43M | $-28.68M | $-9.14M | $-16.10M | $-16.10M | $-2.68M | $-2.68M | $-2.68M | $-2.68M |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $-35.00K | $98.03M | $- | $- | $324.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $10.03M | $- | $- | $- | $- | $- | $- | $- | $-508.75K | $-508.75K | $-508.75K | $-508.75K |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $-16.16M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-14.78M | $-8.12M | $-9.38M | $90.42M | $36.58M | $47.68M | $8.48M | $-11.71M | $-12.89M | $215.16M | $175.82M | $65.93M | $-11.76M | $-11.76M | $-13.31M | $-13.31M | $-3.48M | $-3.48M |
| Net Cash Used Provided by Financing Activities | $-14.78M | $-8.12M | $-7.25M | $90.42M | $36.58M | $47.68M | $-7.67M | $-11.71M | $-12.89M | $215.16M | $175.82M | $65.93M | $-11.76M | $-11.76M | $-13.31M | $-13.31M | $-13.31M | $-13.31M |
| Effect of Forex Changes on Cash | $-80.00K | $2.91M | $4.05M | $-5.61M | $-6.96M | $-1.82M | $-349.00K | $-11.10M | $1.74M | $2.88M | $1.15M | $521.00K | $70.64M | $70.64M | $30.96M | $30.96M | $30.96M | $30.96M |
| Net Change in Cash | $-42.71M | $-31.96M | $-35.26M | $28.82M | $-59.60M | $33.90M | $-85.58M | $-28.73M | $-88.06M | $173.35M | $123.62M | $-9.46M | $5.45M | $5.45M | $-7.97M | $-7.97M | $-7.97M | $-7.97M |
| Cash at End of Period | $25.34M | $68.05M | $100.01M | $135.26M | $106.45M | $166.05M | $132.15M | $217.73M | $246.46M | $334.52M | $161.17M | $37.55M | $40.29M | $40.29M | $34.85M | $34.85M | $34.85M | $34.85M |
| Cash at Beginning of Period | $68.05M | $100.01M | $135.26M | $106.45M | $166.05M | $132.15M | $217.73M | $246.46M | $334.52M | $161.17M | $37.55M | $47.01M | $34.85M | $34.85M | $42.82M | $42.82M | $42.82M | $42.82M |
| Operating Cash Flow | $-27.02M | $-25.02M | $-29.68M | $-50.12M | $-82.74M | $-1.70M | $-52.63M | $-24.48M | $-48.63M | $-9.27M | $-24.66M | $-66.77M | $-37.33M | $-37.33M | $-22.94M | $-22.94M | $-22.94M | $-22.94M |
| Capital Expenditure | $-821.00K | $-1.73M | $-2.38M | $-5.88M | $-6.46M | $-10.26M | $-24.93M | $-19.68M | $-26.31M | $-35.43M | $-28.68M | $-9.14M | $-16.10M | $-16.10M | $-2.68M | $-2.68M | $-2.68M | $-2.68M |
| Free Cash Flow | $-27.84M | $-26.75M | $-32.06M | $-55.99M | $-89.21M | $-11.96M | $-77.56M | $-44.16M | $-74.94M | $-44.70M | $-53.34M | $-75.91M | $-53.43M | $-53.43M | $-25.62M | $-25.62M | $-25.62M | $-25.62M |
LumiraDx Dividends
Explore LumiraDx's dividend history, including dividend yield, payout ratio, and historical payments.
LumiraDx News
Read the latest news about LumiraDx, including recent articles, headlines, and updates.
Former Alere and LumiraDx R&D Chief Nigel Lindner Joins CLEU Diagnostics to Launch Revolutionary LabSimple Diagnostic Platform
PHILADELPHIA--(BUSINESS WIRE)--CLEU Diagnostics, the company reimagining comprehensive clinical laboratory testing has expanded its team with the addition of Nigel Lindner, PhD as Chief Innovation Officer. Dr. Lindner brings over three decades of experience in advancing innovation in diagnostics, previously as Global Head of R&D at Alere, CEO of Swiss Precision Diagnostics, and CIO at LumiraDx. “We are incredibly excited about the opportunity to work closely with Dr. Lindner to validate and.
Why Is LumiraDx (LMDX) Stock Down 13% Today?
LumiraDx (NASDAQ: LMDX ) stock is taking a beating on Monday as investors prepare for the point-of-care diagnostics company's shares to be suspended tomorrow. LumiraDx notes that shares of LMDX are going to be suspended from the Nasdaq Exchange at the start of business on Tuesday.
LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th
LONDON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification from The Nasdaq Stock Market LLC (“Nasdaq”) that its securities will be suspended from trading at the open of business on January 9, 2024 as a result of the Company's failure to maintain compliance with Nasdaq's continued listing standards.
LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche
LONDON, Dec. 29, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”), a next generation point of care diagnostics company, announced today the appointment of joint administrators for two of its subsidiaries. The administrators have signed a definitive agreement to sell certain companies of the LumiraDx group related to LumiraDx's innovative point of care technology to Roche.
LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal
LONDON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- On October 24, 2023, LumiraDx Limited (Nasdaq: LMDX)(the “Company”) received a notice (“Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that on April 21, 2023, the Staff had notified the Company that the bid price of its listed securities had closed at less than $US1.00 per share over the previous 30 consecutive business days, and, as a result, did not comply with Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). Therefore, in accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until October 18, 2023, to regain compliance with the Minimum Bid Price Requirement. The Notice states that because the Company has not regained compliance with the Minimum Bid Price Requirement, its securities are now subject to delisting from The Nasdaq Global Market.
Why Is LumiraDx (LMDX) Stock Up 323% Today?
LumiraDx (NASDAQ: LMDX ) stock is taking off on Monday with a new partnership with AstraZeneca (NASDAQ: AZN ) behind its rally. This collaboration has LumiraDx working together with AstraZeneca and Everton in the Community to set up the first community-based heart and lung screening hub in England.
LumiraDx Limited (LMDX) Loses -25.54% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
LumiraDx Limited (LMDX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LumiraDx Limited (LMDX) Q2 2023 Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q2 2023 Earnings Call Transcript August 24, 2023 8:30 AM ET Company Participants Melissa Garcia - Vice President Corporate Counsel Ron Zwanziger - Chairman & Chief Executive Officer Dorian LeBlanc - Chief Financial Officer Conference Call Participants Matt Sykes - Goldman Sachs Jeffrey Cohen - Ladenburg Thalmann Andrew Cooper - Raymond James Mark Massaro - BTIG Operator Good day and thank you for standing by. Welcome to the LumiraDx Second Quarter 2023 Earnings Conference Call.
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24
LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 24, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests
Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany Axonlab Secures Exclusive Distribution Rights in Swiss Market and Additional Non-Exclusive Distribution Rights in Germany
Why Is LumiraDx (LMDX) Stock Up 30% Today?
LumiraDx (NASDAQ: LMDX ) stock is heading higher on Wednesday morning after the company received approval for its Covid and RSV tests. The U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) gave its approval to the company's test through its Coronavirus Test Device Approvals (CTDA) process.
LumiraDx to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Quarterly Conference Call on March 21
LONDON, March 14, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2022 financial results on Tuesday, March 21st, 2023. On the day of the release, LumiraDx will host a conference call and webcast at 8:30 AM Eastern Time to review the financial results and business highlights.
LumiraDx to Present at Raymond James Institutional Investors Conference
LONDON, March 03, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX) (the “Company”) today announced that Chief Financial Officer, Dorian LeBlanc, will be presenting at the Raymond James Institutional Investors Conference on Tuesday, March 7th, 2023 at 4:35pm ET. Webcast link below.
LumiraDx Limited (LMDX) Q3 2022 Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q3 2022 Results Conference Call November 9, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Tallman Andrew Cooper - Raymond James Operator Good day and thank you for standing by. Thank you for joining LumiraDx Third Quarter 2022 Earnings Conference Call.
LumiraDx to Announce Third Quarter Financial Results and Host Quarterly Conference Call on November 9
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its third quarter financial results on Wednesday, November 9th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
LumiraDx Partners with British In Vitro Diagnostics Association to Report on the Role of Rapid Diagnostics in Tackling Antimicrobial Resistance
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic” Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim of efforts to tackle the next hidden pandemic”
LumiraDx Limited's (LMDX) CEO Ron Zwanziger on Q2 2022 Results - Earnings Call Transcript
LumiraDx Limited (NASDAQ:LMDX ) Q2 2022 Earnings Conference Call August 18, 2022 8:00 AM ET Company Participants Colleen McMillen - Vice President, Communications Ron Zwanziger - Chairman and CEO Dorian LeBlanc - Chief Financial Officer Pooja Pathak - Chief Product Officer Conference Call Participants Vijay Kumar - Evercore ISI Jeffrey Cohen - Ladenburg Mark Massaro - BTIG Operator Good day. And welcome to the LumiraDx Second Quarter 2022 Earnings Call.
LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 18
LONDON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its second quarter financial results on Thursday, August 18th, 2022. On the day of the release, LumiraDx will host a conference call and webcast at 8:00 AM Eastern Time to review the financial results and business highlights.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LMDX.